Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Cassava Sciences ( (SAVA) ).
On February 19, 2026, Cassava Sciences announced that the U.S. Department of Justice Fraud Section has closed its inquiry into the company over allegations of research misconduct tied to the now-dismissed criminal case United States v. Wang, whose indictment was thrown out with prejudice on October 23, 2025. Cassava also noted it had previously settled negligence-based disclosure charges with the Securities and Exchange Commission in September 2024 by paying a monetary penalty, and said the conclusion of both the DOJ and SEC matters removes a major legal overhang as management shifts focus back to advancing its investigational treatment for TSC-related epilepsy.
The most recent analyst rating on (SAVA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Cassava Sciences stock, see the SAVA Stock Forecast page.
Spark’s Take on SAVA Stock
According to Spark, TipRanks’ AI Analyst, SAVA is a Neutral.
The score is driven down primarily by weak financial performance (no revenue, sizable losses, and continued cash burn) and bearish technical trends (below major moving averages with negative MACD). Valuation also offers limited support due to a negative P/E and no dividend.
To see Spark’s full report on SAVA stock, click here.
More about Cassava Sciences
Cassava Sciences, Inc., based in Austin, Texas, is a Nasdaq-listed biotechnology company focused on developing novel investigational treatments for central nervous system disorders. Its pipeline includes the drug candidate simufilam and programs targeting conditions such as tuberous sclerosis complex-related epilepsy and potentially other neurological indications.
The company’s strategy centers on high-risk, early-stage drug discovery and development, with no products yet approved for sale in any jurisdiction. Cassava emphasizes that its R&D programs remain investigational, with earlier-stage clinical and preclinical results not necessarily predictive of outcomes in larger, later-stage trials or of eventual regulatory approval.
Average Trading Volume: 917,635
Technical Sentiment Signal: Strong Sell
Current Market Cap: $101M
For detailed information about SAVA stock, go to TipRanks’ Stock Analysis page.
